Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

44 Press Releases
DateTitleCompany
26 Jun 17 Shire to present new data at ISTH 2017 to advance the standard of care in Hemophilia Shire,
Published by
PharmiWeb.com
26 Jun 17 Shire announces EMA validation of VEYVONDI™ [von Willebrand factor (Recombinant)] Marketing Authorization Application for treatment of von Willebrand disease Shire,
Published by
PharmiWeb.com
26 Jun 17 Director Declaration Shire,
Published by
PharmiWeb.com
23 Jun 17 SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA Shire Pharmaceuticals Group,
Published by
GlobeNewswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
22 Jun 17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease Shire plc,
Published by
PR Newswire
26 May 17 Shire to Participate at the Jefferies Healthcare Conference Shire ,
Published by
PharmiWeb.com
25 May 17 Shire to Participate at the Jefferies Healthcare Conference Shire plc,
Published by
PR Newswire
22 May 17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis Shire ,
Published by
PharmiWeb.com
22 May 17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Shire,
Published by
PharmiWeb.com
21 May 17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology Shire ,
Published by
PharmiWeb.com
19 May 17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology Shire plc,
Published by
PR Newswire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.